| pubmed-article:20137810 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C0012550 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C0870134 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C0021757 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C0004891 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C1446409 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C0162768 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C1268567 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C2757011 | lld:lifeskim |
| pubmed-article:20137810 | lifeskim:mentions | umls-concept:C0162388 | lld:lifeskim |
| pubmed-article:20137810 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:20137810 | pubmed:dateCreated | 2010-6-11 | lld:pubmed |
| pubmed-article:20137810 | pubmed:abstractText | Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib. This study was designed to determine if targeting the interleukin-3 receptor (IL-3R) with a diphtheria toxin fusion protein (DT(388)IL3) would improve the effectiveness of TKIs against Ph(+) AL cells. IL-3R subunits were detected on most Ph(+) cells and the IC50 for killing of colony forming cell (CFC) with DT(388)IL3 correlated with the level of IL-3Ralpha subunit by FACS. DT(388)IL3 synergized with both imatinib and dasatinib for killing of malignant CFCs. Long-term suspension culture-initiating cells (SC-ICs) and quiescent leukemic cells (G(0) in cell cycle) also were studied and synergistic interactions were again demonstrated. Thus, cotreatment with TKIs and DT(388)IL3 is much more effective in eliminating Ph(+) leukemic progenitors that express IL-3R than either agent alone. | lld:pubmed |
| pubmed-article:20137810 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20137810 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20137810 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20137810 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20137810 | pubmed:issn | 1873-5835 | lld:pubmed |
| pubmed-article:20137810 | pubmed:author | pubmed-author:FrankelArthur... | lld:pubmed |
| pubmed-article:20137810 | pubmed:author | pubmed-author:HoggeDonna... | lld:pubmed |
| pubmed-article:20137810 | pubmed:author | pubmed-author:KimHyun PyoHP | lld:pubmed |
| pubmed-article:20137810 | pubmed:copyrightInfo | Copyright (c) 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20137810 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20137810 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:20137810 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20137810 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20137810 | pubmed:pagination | 1035-42 | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:meshHeading | pubmed-meshheading:20137810... | lld:pubmed |
| pubmed-article:20137810 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20137810 | pubmed:articleTitle | A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. | lld:pubmed |
| pubmed-article:20137810 | pubmed:affiliation | Terry Fox Laboratory, British Columbia Cancer Agency and Department of Medicine, University of British Columbia, 675 West 10 Ave., Vancouver, BC, V5Z 1L3 Canada. | lld:pubmed |
| pubmed-article:20137810 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20137810 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
